Business Context and Reporting Period
This Form 8-K Current Report was filed by Anteris Technologies Global Corp. (AVR) on March 5, 2025. The report discloses a significant corporate governance event: the appointment of David St Denis as President and a Class II director of the Board, effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Appointment: David St Denis was appointed President and Class II director.
- Role Transition: Mr. St Denis previously served as Chief Operating Officer since July 2017 and will now assume the role of President.
- Board Composition: Mr. St Denis is classified as a non-independent director and will not serve on any Board committees.
Guidance, Outlook, and Risks
Management Commentary: The filing details Mr. St Denis's extensive background, including roles at Merck, Millennium Pharmaceuticals (now Takeda), and v2vmedtech, inc. He holds an MBA from Babson College.
Compensation: There has been no material amendment to Mr. St Denis's current compensatory arrangements, and no new grants or awards were issued in connection with this appointment.
Risks and Contingencies: The filing confirms no family relationships between Mr. St Denis and other directors/officers and no material interest in transactions requiring disclosure under Item 404(a). An indemnification agreement, previously executed for his role as COO, remains in effect.
Investor Verification Checklist
- Verify the effective date of the President appointment (March 5, 2025).
- Confirm that no new equity grants or compensation changes accompanied the promotion.
- Review the attached Director and Officer Indemnification Agreement (Exhibit 10.2 from Amendment No. 1 to Form S-1) for liability terms.
- Check subsequent filings for any changes to the Board's committee structure resulting from this appointment.